

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-102 are canceled

103. (New) A pharmaceutical formulation for delivery of a mixture of amphetamine base salts effective to treat ADHD in a human patient comprising:

an immediate release dosage form that provides immediate release upon oral administration to said patient;

a delayed enteric release dosage form that provides delayed release upon oral administration to said patient; and

a pharmaceutically acceptable carrier;

wherein said amphetamine base salts comprise dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate and amphetamine sulfate;

wherein said pharmaceutical composition is sufficient to maintain an effective level of amphetamine base salts in the patient over the course of at least 8 hours without further administration of amphetamine base salt, and the peak plasma concentration of amphetamine base salts reached after release of said delayed enteric release dosage form exceeds the peak plasma concentration previously reached after release of said immediate release dosage form; and

wherein said pharmaceutical composition produces in a human individual a plasma concentration versus time curve (ng/ml versus hours) having an area under the curve (AUC) of about 467 to about 714 ng hr/ml, for about a 20 mg total dose, or an AUC proportional thereto for a total dose other than about 20 mg.

104. (New) A formulation of claim 103 wherein said plasma concentration curve has a maximum concentration (C_{max}) of about 22.5 to about 40 ng/ml for about a 10 mg dose in each

of said dosage forms, or a C_{max} proportional thereto for a dose in each of said dosage forms other than about 10 mg.

105. (New) A formulation of claim 104 wherein the time after said oral administration to reach said C_{max} value is about 7 to about 10 hours.

106. (New) A formulation of claim 103 wherein the time after said oral administration to reach maximum concentration of said plasma concentration curve is about 7 to about 10 hours.

107. (New) A formulation of claim 104, 105 or 106 wherein said AUC is about 714 ng hr/ml.

108. (New) A formulation of claim 105 wherein said AUC is about 714 ng hr/ml, the time after said oral administration to reach said C_{max} value is about 7 hours and C_{max} is about 40 ng/ml.

109. (New) A formulation of claim 104 wherein C_{max} is about 40 ng/ml.

110. (New) A formulation of claim 105 or 106 wherein said time is about 7 hours.

111. (New) A formulation of one of claims 103-106, 108 or 109 wherein said salts are contained in about equal amounts within each of said dosage forms and the total amphetamine salt amount in each of said dosage forms is about the same.

112. (New) A formulation of one of claims 103-106, 108 or 109 wherein said delayed enteric release dosage form comprises a coating of a thickness of at least 20 μ m which comprises dried 30% (dry substance) aqueous dispersion of an anionic copolymer based on methacrylic acid and acrylic acid ethyl ester, said coating being soluble at a pH of 5.5 upwards.

113. (New) A formulation of claim 112 wherein said thickness is at least 25 μm .

114. (New) A pharmaceutical formulation for delivery of a mixture of amphetamine base salts effective to treat ADHD in a human patient comprising:
an immediate release dosage form that provides immediate release upon oral administration to said patient;

a delayed enteric release dosage form that provides delayed release upon oral administration to said patient, wherein said enteric release dosage form comprises a coating of a thickness of at least 20 μm which comprises dried 30% (dry substance) aqueous dispersion of an anionic copolymer based on methacrylic acid and acrylic acid ethyl ester, said coating being soluble at a pH of 5.5 upwards; and

a pharmaceutically acceptable carrier;

wherein said amphetamine base salts comprise dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate and amphetamine sulfate;

wherein said pharmaceutical composition is sufficient to maintain an effective level of amphetamine base salts in the patient over the course of at least 8 hours without further administration of amphetamine base salt, and the peak plasma concentration of amphetamine base salts reached after release of said delayed enteric release dosage form exceeds the peak plasma concentration of said salts previously reached after release of said immediate release dosage form.

115. (New) A formulation of claim 114 wherein said thickness is at least 25 μm .